8th Jun 2006 07:03
AstraZeneca PLC08 June 2006 AstraZeneca Development Pipeline 8 June 2006 Line Extensions Compound Mechanism Area under investigation Phase Estimated Filing MAA NDACVAtacand angiotensin II antagonist diabetic retinopathy III > 2008 >2008Atacand Plus angiotensin II antagonist / 32/12.5 mg, 32/25 mg for III 2008 thiazide diuretic hypertensionCrestor statin atherosclerosis III 1H 2007 1H 2007Crestor statin outcomes CHF III >2008 >2008Crestor statin outcomes renal III 2008 2008Seloken/Toprol-XL beta-blocker HCTZ combination III Launched Filed GI Nexium proton pump inhibitor NSAID GI side effects - III Promotable* Filed symptom resolutionNexium proton pump inhibitor NSAID GI side effects - III Launched Filed ulcer healingNexium proton pump inhibitor peptic ulcer bleeding III >2008 >2008Nexium Sachet proton pump inhibitor GERD III Q4 2006 FiledformulationNexium proton pump inhibitor extra-oesophageal reflux II >2008 >2008 disease Neuroscience Seroquel SR D2/5HT2 antagonist schizophrenia III 4Q 2006 3Q 2006Seroquel D2/5HT2 antagonist bipolar maintenance III 2H 2007 1H 2007Seroquel D2/5HT2 antagonist bipolar depression III 1H 2007 FiledSeroquel SR D2/5HT2 antagonist generalised anxiety III 2008 2H 2007 disorderSeroquel SR D2/5HT2 antagonist major depressive III 2008 2008 disorderOnc/infection Faslodex oestrogen receptor antagonist 2nd line after aromatase III 1 H2007 1 H 2007 inhibitor failureFaslodex oestrogen receptor antagonist 1st line advanced breast III >2008 >2008 cancerFaslodex oestrogen receptor antagonist adjuvant III >2008 >2008Iressa EGFR-TK inhibitor head & neck cancer III 2H 2007 1H 2007Iressa EGFR-TK inhibitor breast cancer II >2008 >2008 * Authorities stated these symptoms were already captured within the GERD label.Text stating "No clinical interaction with naproxen or rofecoxib" was approved. Compound Mechanism Area under investigation Phase Estimated Filing MAA NDARespiratory Symbicort Turbuhaler inhaled steroid/fast onset, Symbicort Maintenance III Filed long-acting ss2 agonist and Reliever Therapy for asthma (SMART)Symbicort pMDI inhaled steroid/fast onset, asthma III Filed* Filed long-acting ss2 agonist Symbicort pMDI inhaled steroid/fast onset, COPD III Filed* 2008 long-acting ss2 agonist * To be supplemented in 2008 with data supporting two additional strengths NCE's Phase III Compound Mechanism Area under investigation Phase Estimated Filing MAA NDACV AGI-1067 Anti-atherogenic atherosclerosis III 1H 2007 1H 2007AZD6140 ADP receptor antagonist arterial thrombosis III >2008 >2008NeuroscienceNXY-059 free radical trapping agent stroke III 1H 2007 1H 2007 Oncology/InfZactima VEGF/EGF TKI inhibitor with NSCLC III >2008 >2008 RET kinase activity AZD2171 VEGF signalling inhibitor II/III >2008 >2008 (VEGFR-TKI) NSCLC and CRC NCE's Phases I and II Compound Mechanism Area under investigation Phase Estimated Filing MAA NDACVAZD7009 antiarrhythmic IV atrial fibrillation - II 2008 2008 conversionAZD9684 CPU inhibitor thrombosis II >2008 >2008AZD0837 thrombin inhibitor thrombosis II >2008 >2008AZD2479 Reverse Cholesterol Transport dyslipidaemia I >2008 >2008 enhancerAZD6610 PPAR alpha with "partial combined dyslipidaemia I >2008 >2008 gamma"AZD8677 dyslipidaemia/ I >2008 >2008 diabetesGIAZD9056 Ion channel blocker (P2X7) inflammatory bowel II >2008 >2008 diseaseAZD3355 inhibitor of transient lower GERD I >2008 >2008 oesophageal sphincter relaxations (TLESR)AZD9272 Glutamate receptor modulator GERD I >2008 >2008NeuroscienceAZD3480 Neuronal nicotinic receptor cognitive disorders/ II >2008 >2008 agonist alzheimersAZD9272 Glutamate receptor modulator neuropathic pain/anxiety I >2008 >2008AZD2327 Enkephalinergic receptor anxiety & depression I >2008 >2008 modulatorAZD5904 Enzyme inhibitor multiple sclerosis I >2008 >2008AZD1080 Alzheimers I >2008 >2008Onc/Infection Zactima VEGF/EGF TKI inhibitor with medullary thyroid cancer II >2008 >2008 RET kinase activity CytoFab anti-TNF-alpha polyclonal severe sepsis II >2008 >2008 antibodyZD4054 endothelin A receptor prostate cancer II >2008 >2008 antagonistAZD5896 (Patrin) AGT inhibitor solid tumours II >2008 >2008AZD0530 SRC kinase inhibitor solid tumours and I >2008 >2008 haematological malignanciesAZD6244 MEK inhibitor solid tumours II >2008 >2008(ARRY-142886)AZD1152 Aurora kinase inhibitor solid tumours and I >2008 >2008 haematological malignanciesAZD4769 solid tumours I >2008 >2008AZD2281 (KU59436) PARP inhibitor breast cancer I >2008 >2008AZD1689 (AQ4N) Hypoxia activated cytotoxic solid tumours I >2008 >2008 Phases I and II (continued) Compound Mechanism Area under Phase Estimated Filing investigation MAA NDARespiratoryAZD9056 ion channel blocker (P2X7) rheumatoid arthritis II >2008 >2008AZD9056 ion channel blocker (P2X7) COPD II >2008 >2008AZD8955 collagenase inhibitor osteoarthritis II >2008 >2008AZD8309 chemokine receptor antagonist rheumatoid arthritis I >2008 >2008AZD8309 chemokine receptor antagonist COPD I >2008 >2008AZD3342 Protease inhibitor COPD I >2008 >2008AZD1981 asthma I >2008 >2008AZD5672 rheumatoid arthritis I >2008 >2008AZD5904 COPD I >2008 >2008 NCE's Pre Clinical Compound Mechanism Area of investigation Phase Estimated Filing MAA NDACV AZD8450 dyslipidaemia PC >2008 >2008AZD6370 diabetes PC >2008 >2008AZD8593 haemostasis PC >2008 >2008AZD1175 diabetes/obesity PC >2008 >2008AZD2207 diabetes/obesity PC >2008 >2008AZD1305 arrhythmias PC >2008 >2008AZD4121 Cholesterol absorption dyslipidaemia PC >2008 >2008 inhibitorGI AZD8081 functional GI disease PC >2008 >2008AZD9335 GERD PC >2008 >2008Neuroscience AZD3102 Alzheimers PC >2008 >2008AZD6538 neuropathic pain PC >2008 >2008AZD8797 multiple sclerosis PC >2008 >2008AZD3783 anxiety and depression PC >2008 >2008AZD1940 nociceptive and PC >2008 >2008 neuropathic pain.AZD9335 neuropathic pain PC >2008 >2008AZD3241 Parkinson's disease PC >2008 >2008AZD7512 depression & anxiety PC >2008 >2008AZD3043 (TD-4756, GABA-A receptor modulator short acting PC >2008 >2008Theravance) anaesthetic Pre Clinical (continued) Compound Mechanism Area of investigation Phase Estimated Filing MAA NDAOnc/Infection AZD9935 VEGF signalling inhibitor solid tumours PC >2008 >2008 (VEGFR-TKI)AZD0424 SRC kinase inhibitor solid tumours PC >2008 >2008AZD8931 solid tumours PC >2008 >2008AZD4877 solid tumours PC >2008 >2008AZD7762 solid tumours PC >2008 >2008AZD5180 Anti-angiogenic solid tumours PC >2008 >2008AZD1845 solid tumours PC >2008 >2008AZD8330 solid tumours PC >2008 >2008AZD3646 solid tumours and PC >2008 >2008 haematological malignanciesRespiratory AZD6067 protease inhibitor COPD PC >2008 >2008AZD6703 rheumatoid arthritis PC >2008 >2008AZD6357 osteoarthritis PC >2008 >2008AZD7928 COPD PC >2008 >2008AZD2392 asthma/rhinitis PC >2008 >2008AZD1744 asthma/rhinitis PC >2008 >2008AZD3825 asthma PC >2008 >2008AZD1236 COPD PC >2008 >2008AZD4818 COPD PC >2008 >2008AZD5069 COPD PC >2008 >2008AZD9668 COPD PC >2008 >2008AZD9215 asthma PC >2008 >2008AZD1678 asthma PC >2008 >2008AZD6605 osteoarthritis PC >2008 >2008 AstraZeneca Development PipelineDiscontinued Projects vs Annual Results 2 February 2006 CVGI NCE/Line Extension Compound Area under investigationLE Exanta prevention of stroke in AFNCE AZD1092 DiabetesNCE Galida Diabetes/ Metabolic Syndrome NCE AZD9343 GERDNCE AZD6538 GERD Respiratory and Inflammation NCE/Line Extension Compound Area under investigationNCE AZD3778 Indication rhinitisNCE AZD2914 COPD Comments As disclosure of compound information is balanced by the business need tomaintain confidentiality, information in relation to some compounds listed herehas not been disclosed at this time. Compounds in development are displayed by phase. Abbreviations: PC - Pre-clinical: Candidate Drug accepted for development but not yetadministered to man. MAA - Marketing Authorisation Application (Europe) NDA - New Drug Application (USA) This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca